Commonly asked questions in the treatment of obsessive-compulsive disorder

References

• Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder [see commetns]. Arch Gen Psychiatry 1999;56(2):121-7
   PubMed Web of Science ®Google Scholar
• Foa EB. Cognitive behavioral therapy of obsessive-compulsive disorder. Dialogues Clin Neurosci 2010;12(2):199-207
   PubMedGoogle Scholar
• Dell'Osso B, Altamura AC, Allen A, Hollander E. Brain stimulation techniques in the treatment of obsessive-compulsive disorder: current and future directions. CNS Spectr 2005;10(12):966-79; 983
   PubMedGoogle Scholar
• Fineberg NA, Reghunandanan S, Brown A, Pampaloni I. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust N Z J Psychiatry 2013;47(2):121-41
   PubMed Web of Science ®Google Scholar
• Arumugham SS, Reddy JYC. Augmentation strategies in obsessive-compulsive disorder. Expert Rev Neurother 2013;13(2):187-202. quiz 203
   PubMed Web of Science ®Google Scholar
• Ponniah K, Magiati I, Hollon SD. An update on the efficacy of psychological therapies in the treatment of obsessive-compulsive disorder in adults. J Obsessive Compuls Relat Disord 2013;2(2):207-18
   PubMed Web of Science ®Google Scholar
• Jaafari N, Rachid F, Rotge J-Y, et al. Safety and efficacy of repetitive transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: a review. World J Biol Psychiatry 2012;13(3):164-77
   PubMed Web of Science ®Google Scholar
• Greenberg BD, Rauch SL, Haber SN. Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD. Neuropsychopharmacol 2010;35(1):317-36
   PubMedGoogle Scholar
• Koran LM, Hanna GL, Hollander E, et al. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007;164(7 Suppl):5-53
   PubMed Web of Science ®Google Scholar
• Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2008;(1):CD001765
   Google Scholar
• Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 2004;24(8):1011-30
   PubMedGoogle Scholar
• National Collaborating Centre for Mental Health. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. British. Psychological Society & The Royal College of Psychiatrists; Leicester, UK: 2006
   Google Scholar
• Rosa-Alcázar AI, Sánchez-Meca J, Gómez-Conesa A, Marín-Martínez F. Psychological treatment of obsessive-compulsive disorder: a meta-analysis. Clin Psychol Rev 2008;28(8):1310-25
   PubMed Web of Science ®Google Scholar
• Olatunji BO, Davis ML, Powers MB, Smits JAJ. Cognitive-behavioral therapy for obsessive-compulsive disorder: a meta-analysis of treatment outcome and moderators. J Psychiatr Res 2013;47(1):33-41
   PubMed Web of Science ®Google Scholar
• Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005;162(1):151-61
   PubMed Web of Science ®Google Scholar
• Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am J Psychiatry 2008;165(5):621-30
   PubMed Web of Science ®Google Scholar
• Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry 2013;70(11):1190-9
   PubMed Web of Science ®Google Scholar
• Abramowitz JS. Variants of exposure and response prevention in the treatment of obsessive-compulsive disorder: a meta-analysis. Behav Ther 1996;27(4):583-600
   Web of Science ®Google Scholar
• Van Oppen P, van Balkom AJLM, Smit JH, et al. Does the therapy manual or the therapist matter most in treatment of obsessive-compulsive disorder? A randomized controlled trial of exposure with response or ritual prevention in 118 patients. J Clin Psychiatry 2010;71(9):1158-67
   PubMedGoogle Scholar
• Greist JH, Marks IM, Baer L, et al. Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J Clin Psychiatry 2002;63(2):138-45
   PubMed Web of Science ®Google Scholar
• Kenwright M, Marks I, Graham C, et al. Brief scheduled phone support from a clinician to enhance computer-aided self-help for obsessive-compulsive disorder: randomized controlled trial. J Clin Psychol 2005;61(12):1499-508
   PubMedGoogle Scholar
• Math SB, Janardhan Reddy YC. Issues in the pharmacological treatment of obsessive-compulsive disorder. Int J Clin Pract 2007;61(7):1188-97
   PubMed Web of Science ®Google Scholar
• Bloch MH, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry 2010;15(8):850-5
   PubMed Web of Science ®Google Scholar
• Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 2006;67(1):15-22
   PubMed Web of Science ®Google Scholar
• Diniz JB, Shavitt RG, Fossaluza V, et al. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol 2011;31(6):763-8
   PubMed Web of Science ®Google Scholar
• Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 1990;28(5):401-14
   PubMed Web of Science ®Google Scholar
• Da Conceição Costa DL, Shavitt RG, Castro Cesar RC, et al. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. J Psychiatr Res 2013;47(11):1700-7
   PubMed Web of Science ®Google Scholar
• Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 1990;5(1):17-30
   PubMedGoogle Scholar
• Kobak KA, Greist JH, Jefferson JW, et al. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl) 1998;136(3):205-16
   PubMedGoogle Scholar
• Sousa MB, Isolan LR, Oliveira RR, et al. A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 2006;67(7):1133-9
   PubMed Web of Science ®Google Scholar
• Belotto-Silva C, Diniz JB, Malavazzi DM, et al. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial. J Anxiety Disord 2012;26(1):25-31
   PubMed Web of Science ®Google Scholar
• Simpson HB, Liebowitz MR, Foa EB, et al. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety 2004;19(4):225-33
   PubMedGoogle Scholar
• Diniz JB, Malavazzi DM, Fossaluza V, et al. Risk factors for early treatment discontinuation in patients with obsessive-compulsive disorder. Clinics (São Paulo) 2011;66(3):387-93
   PubMedGoogle Scholar
• Clark DA. Focus on “cognition” in cognitive behavior therapy for OCD: is it really necessary? Cogn Behav Ther 2005;34(3):131-9
   PubMedGoogle Scholar
• Salkovskis PM, Westbrook D. Behaviour therapy and obsessional ruminations: can failure be turned into success? Behav Res Ther 1989;27(2):149-60
   PubMedGoogle Scholar
• Salkovskis PM, Warwick HMC. Cognitive therapy of obsessive–compulsive disorder: treating treatment failures. Behav Cogn Psychother 1985;13(03):243-55
   Google Scholar
• Abramowitz JS, Taylor S, McKay D. Potentials and limitations of cognitive treatments for obsessive-compulsive disorder. Cogn Behav Ther 2005;34(3):140-7
   PubMedGoogle Scholar
• Whittal ML, Woody SR, McLean PD, et al. Treatment of obsessions: a randomized controlled trial. Behav Res Ther 2010;48(4):295-303
   PubMedGoogle Scholar
• O'Connor K, Freeston MH, Gareau D, et al. Group versus individual treatment in obsessions without compulsions. Clin Psychol Psychother 2005;12(2):87-96
   Google Scholar
• Krochmalik A, Jones MK, Menzies RG, Kirkby K. The superiority of danger ideation reduction therapy (DIRT) over exposure and response prevention (ERP) in treating compulsive washing. Behav Change 2004;21(4):251
   Google Scholar
• Hu X-Z, Wen Y-S, Ma J-D, et al. A promising randomized trial of a new therapy for obsessive-compulsive disorder. Brain Behav 2012;2(4):443-54
   PubMedGoogle Scholar
• Ma J-D, Wang C-H, Li H-F, et al. Cognitive-coping therapy for obsessive-compulsive disorder: a randomized controlled trial. J Psychiatr Res 2013;47(11):1785-90
   PubMedGoogle Scholar
• Twohig MP, Hayes SC, Plumb JC, et al. A randomized clinical trial of acceptance and commitment therapy versus progressive relaxation training for obsessive-compulsive disorder. J Consult Clin Psychol 2010;78(5):705-16
   PubMed Web of Science ®Google Scholar
• Khodarahimi S. Satiation therapy and exposure response prevention in the treatment of obsessive compulsive disorder. J Contemp Psychother 2009;39(3):203-7
   Google Scholar
• Hanstede M, Gidron Y, Nyklícek I. The effects of a mindfulness intervention on obsessive-compulsive symptoms in a non-clinical student population. J Nerv Ment Dis 2008;196(10):776-9
   PubMed Web of Science ®Google Scholar
• Hertenstein E, Rose N, Voderholzer U, et al. Mindfulness-based cognitive therapy in obsessive-compulsive disorder - A qualitative study on patients' experiences. BMC Psychiatry 2012;12:185
   PubMedGoogle Scholar
• Wilkinson-Tough M, Bocci L, Thorne K, Herlihy J. Is mindfulness-based therapy an effective intervention for obsessive-intrusive thoughts: a case series. Clin Psychol Psychother 2010;17(3):250-68
   PubMed Web of Science ®Google Scholar
• Shannahoff-Khalsa DS, Ray LE, Levine S, et al. Randomized controlled trial of yogic meditation techniques for patients with obsessive-compulsive disorder. CNS Spectr 1999;4(12):34-47
   PubMedGoogle Scholar
• Albert U, Barbaro F, Aguglia A, et al. Combined treatments in obsessive-compulsive disorder: current knowledge and future prospects. Riv Psichiatr 2012;47(4):255-68
   PubMedGoogle Scholar
• Marks IM, Stern RS, Mawson D, et al. Clomipramine and exposure for obsessive-compulsive rituals: i. Br J Psychiatry 1980;136:1-25
   PubMed Web of Science ®Google Scholar
• Hohagen F, Winkelmann G, Rasche-Rüchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry Suppl 1998(35):71-8
   PubMedGoogle Scholar
• Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004;292(16):1969-76
   PubMed Web of Science ®Google Scholar
• Franklin ME, Sapyta J, Freeman JB, et al. Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial. JAMA 2011;306(11):1224-32
   PubMed Web of Science ®Google Scholar
• Tolin DF, Hannan S, Maltby N, et al. A randomized controlled trial of self-directed versus therapist-directed cognitive-behavioral therapy for obsessive-compulsive disorder patients with prior medication trials. Behav Ther 2007;38(2):179-91
   PubMedGoogle Scholar
• Tenneij NH, van Megen HJGM, Denys DAJP, Westenberg HGM. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry 2005;66(9):1169-75
   PubMedGoogle Scholar
• Albert U, Aguglia A, Bogetto F, et al. Effectiveness of cognitive-behavioral therapy addition to pharmacotherapy in resistant obsessive-compulsive disorder: a multicenter study. Psychother Psychosom 2012;81(6):383-5
   PubMedGoogle Scholar
• Anand N, Sudhir PM, Math SB, et al. Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study. J Anxiety Disord 2011;25(7):939-45
   PubMedGoogle Scholar
• Foa EB, Steketee G, Kozak MJ, Dugger D. Imipramine and placebo in the treatment of obsessive-compulsives: their effect on depression and on obsessional symptoms. Psychopharmacol Bull 1987;23(1):8-11
   PubMedGoogle Scholar
• Bergeron R, Ravindran AV, Chaput Y, et al. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J Clin Psychopharmacol 2002;22(2):148-54
   PubMed Web of Science ®Google Scholar
• Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin 2007;23(4):701-11
   PubMed Web of Science ®Google Scholar
• Alaghband-Rad J, Hakimshooshtary M. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD). Eur Child Adolesc Psychiatry 2009;18(3):131-5
   PubMed Web of Science ®Google Scholar
• Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 1997;17(4):267-71
   PubMedGoogle Scholar
• Geller DA, Biederman J, Stewart SE, et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003;160(11):1919-28
   PubMed Web of Science ®Google Scholar
• Bisserbe J, Lane R, Flament M; Franco-Belgian OCD Study Group. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 1997;12(2):82-93
   PubMed Web of Science ®Google Scholar
• López-Ibor JJ Jr, Saiz J, Cottraux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 1996;6(2):111-18
   PubMed Web of Science ®Google Scholar
• Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996;169(4):468-74
   PubMed Web of Science ®Google Scholar
• Mundo E, Rouillon F, Figuera ML, Stigler M. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 2001;16(6):461-8
   PubMed Web of Science ®Google Scholar
• Jakubovski E, Diniz JB, Valerio C, et al. Clinical predictors of long-term outcome in obsessive-compulsive disorder. Depress Anxiety 2013;30(8):763-72
   PubMedGoogle Scholar
• Fineberg NA, Pampaloni I, Pallanti S, et al. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. Int Clin Psychopharmacol 2007;22(6):313-22
   PubMed Web of Science ®Google Scholar
• Grant JE, Mancebo MC, Weinhandl E, et al. Longitudinal course of pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2013;28(4):200-5
   PubMedGoogle Scholar
• Mundo E, Bareggi SR, Pirola R, et al. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol 1997;17(1):4-10
   PubMedGoogle Scholar
• Denys D, van der Wee N, van Megen HJGM, Westenberg HGM. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003;23(6):568-75
   PubMed Web of Science ®Google Scholar
• Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002;63(11):1004-9
   PubMed Web of Science ®Google Scholar
• Koran LM, Gamel NN, Choung HW, et al. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005;66(4):515-20
   PubMed Web of Science ®Google Scholar
• Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 2004;65(10):1394-9
   PubMed Web of Science ®Google Scholar
• Miguel EC, Diniz JB, Joaquim M. Clomipramine and quetiapine augmentation for obsessive compulsive disorder compared with sustained fluoxetine treatment. Poster presentation (F1000 Poster). Miami Beach, FL, USA; 2010
   Google Scholar
• Denys D, van Megen HJGM, van der Wee N, Westenberg HGM. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 2004;65(1):37-43
   PubMedGoogle Scholar
• Hollander E, Friedberg J, Wasserman S, et al. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2003;64(5):546-50
   PubMedGoogle Scholar
• Ravizza L, Albert U, Ceregato A. Venlafaxine in obsessive compulsive disorder. Presented at Fifth International Obsessive Compulsive Disorder Conference; Sardinia, Italy; 2001
   Google Scholar
• Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 2013;16(3):557-74
   PubMed Web of Science ®Google Scholar
• Soltani F, Sayyah M, Feizy F, et al. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol 2010;25(6):509-13
   PubMed Web of Science ®Google Scholar
• Askari N, Moin M, Sanati M, et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2012;26(10):883-92
   PubMed Web of Science ®Google Scholar
• Ghaleiha A, Entezari N, Modabbernia A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res 2013;47(2):175-80
   PubMed Web of Science ®Google Scholar
• Haghighi M, Jahangard L, Mohammad-Beigi H, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl) 2013;228(4):633-40
   PubMed Web of Science ®Google Scholar
• Bruno A, Micò U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 2012;26(11):1456-62
   PubMed Web of Science ®Google Scholar
• Mowla A, Khajeian AM, Sahraian A, et al. Topiramate augmentation in resistant OCD. a double-blind placebo-controlled clinical trial. CNS Spectr 2010; [Epub ahead of print]
   PubMedGoogle Scholar
• Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2011;72(5):716-21
   PubMed Web of Science ®Google Scholar
• Afshar H, Roohafza H, Mohammad-Beigi H, et al. N-Acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2012;32(6):797-803
   PubMed Web of Science ®Google Scholar
• Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2008;23(1):49-53
   PubMedGoogle Scholar
• Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 2002;63(9):796-801
   PubMedGoogle Scholar
• Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 1998;55(10):918-24
   PubMedGoogle Scholar
• Koran LM, Aboujaoude E, Ward H, et al. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2006;26(1):79-83
   PubMed Web of Science ®Google Scholar
• Kushner MG, Kim SW, Donahue C, et al. D-Cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007;62(8):835-8
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008;165(3):335-41. quiz 409
   PubMed Web of Science ®Google Scholar
• Farrell LJ, Waters AM, Boschen MJ, et al. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of d-cycloserine augmented behavior therapy. Depress Anxiety 2013;30(8):723-31
   PubMed Web of Science ®Google Scholar
• Storch EA, Merlo LJ, Bengtson M, et al. D-Cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007;22(4):230-7
   PubMed Web of Science ®Google Scholar
• Meyer E, Souza F, Heldt E, et al. A randomized clinical trial to examine enhancing cognitive-behavioral group therapy for obsessive-compulsive disorder with motivational interviewing and thought mapping. Behav Cogn Psychother 2010;38(3):319-36
   PubMed Web of Science ®Google Scholar
• Simpson HB, Zuckoff AM, Maher MJ, et al. Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive-compulsive disorder. Behav Res Ther 2010;48(10):941-8
   PubMed Web of Science ®Google Scholar
• Meyer E, Shavitt RG, Leukefeld C, et al. Adding motivational interviewing and thought mapping to cognitive-behavioral group therapy: results from a randomized clinical trial. Rev Bras Psiquiatr 2010;32(1):20-9
   PubMedGoogle Scholar
• Van Balkom AJLM, Emmelkamp PMG, Eikelenboom M, et al. Cognitive therapy versus fluvoxamine as a second-step treatment in obsessive-compulsive disorder nonresponsive to first-step behavior therapy. Psychother Psychosom 2012;81(6):366-74
   PubMedGoogle Scholar
• Hantouche EG, Angst J, Demonfaucon C, et al. Cyclothymic OCD: a distinct form? J Affect Disord 2003;75(1):1-10
   PubMed Web of Science ®Google Scholar
• Vieta E. Antidepressants in bipolar depression. Acta Psychiatr Scand 2008;118(5):335-6
   PubMedGoogle Scholar
• Raja M, Azzoni A. Clinical management of obsessive-compulsive-bipolar comorbidity: a case series. Bipolar Disord 2004;6(3):264-70
   PubMed Web of Science ®Google Scholar
• Bisol L, Lara D. Improvement of obsessive-compulsive disorder with divalproex and lamotrigine in two patients with bipolar II disorder. Pharmacopsychiatry 2009;42(01):37-9
   PubMedGoogle Scholar
• Uguz F. Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder. Gen Hosp Psychiatry 2010;32(5):556-8
   PubMedGoogle Scholar
• Zutshi A, Kamath P, Reddy YCJ. Bipolar and nonbipolar obsessive-compulsive disorder: a clinical exploration. Compr Psychiatry 2007;48(3):245-51
   PubMedGoogle Scholar
• Poyurovsky M. Schizo-obsessive disorder. 1st edition. Cambridge University Press; Cambridge, UK: 2013
   Google Scholar
• Pallanti S, Grassi G, Sarrecchia ED, et al. Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications. Front Psychiatry 2011;2:70
   PubMedGoogle Scholar
• Torres AR, Lima MCP. Epidemiology of obsessive-compulsive disorder: a review. Rev Bras Psiquiatr 2005;27(3):237-42
   PubMedGoogle Scholar
• Schirmbeck F, Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol 2012;10(1):88-95
   PubMedGoogle Scholar
• Reznik I, Yavin I, Stryjer R, et al. Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry 2004;37(2):52-6
   PubMedGoogle Scholar
• Van Nimwegen L, de Haan L, van Beveren N, et al. Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. J Clin Psychopharmacol 2008;28(2):214-18
   PubMed Web of Science ®Google Scholar
• Faragian S, Pashinian A, Fuchs C, Poyurovsky M. Obsessive-compulsive symptom dimensions in schizophrenia patients with comorbid obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(6):1009-12
   PubMedGoogle Scholar
• Hwang MY, Kim S-W, Yum SY, Opler LA. Management of schizophrenia with obsessive-compulsive features. Psychiatr Clin North Am 2009;32(4):835-51
   PubMedGoogle Scholar
• Stryjer R, Dambinsky Y, Timinsky I, et al. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study. Int Clin Psychopharmacol 2013;28(2):96-8
   PubMedGoogle Scholar
• Poyurovsky M, Isakov V, Hromnikov S, et al. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. Int Clin Psychopharmacol 1999;14(2):95-100
   PubMedGoogle Scholar
• Reznik I, Sirota P. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol 2000;20(4):410-16
   PubMedGoogle Scholar
• Lysaker PH, Whitney KA. Obsessive-compulsive symptoms in schizophrenia: prevalence, correlates and treatment. Expert Rev Neurother 2009;9(1):99-107
   PubMed Web of Science ®Google Scholar
• Tundo A, Salvati L, Di Spigno D, et al. Cognitive-behavioral therapy for obsessive-compulsive disorder as a comorbidity with schizophrenia or schizoaffective disorder. Psychother Psychosom 2012;81(1):58-60
   PubMedGoogle Scholar
• Hagen K, Solem S, Hansen B. Cognitive behavioural therapy for obsessive-compulsive disorder with comorbid schizophrenia: a case report with repetitive measurements. Behav Cogn Psychother 2013;1-5
   Google Scholar
• Kim S-W, Shin I-S, Kim J-M, et al. Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. J Clin Psychopharmacol 2008;28(3):349-52
   PubMedGoogle Scholar
• Poyurovsky M, Glick I, Koran LM. Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms. J Psychopharmacol 2010;24(6):861-6
   PubMed Web of Science ®Google Scholar
• Bersani FS, Minichino A, Enticott PG, et al. Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: a comprehensive review. Eur Psychiatry 2013;28(1):30-9
   PubMed Web of Science ®Google Scholar
• Mantovani A, Simpson HB, Fallon BA, et al. Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol 2010;13(2):217-27
   PubMed Web of Science ®Google Scholar
• Gomes PVO, Brasil-Neto JP, Allam N, Rodrigues de Souza E. A randomized, double-blind trial of repetitive transcranial magnetic stimulation in obsessive-compulsive disorder with three-month follow-up. J Neuropsychiatry Clin Neurosci 2012;24(4):437-43
   PubMedGoogle Scholar
• Kang JI, Kim C-H, Namkoong K, et al. A randomized controlled study of sequentially applied repetitive transcranial magnetic stimulation in obsessive-compulsive disorder. J Clin Psychiatry 2009;70(12):1645-51
   PubMed Web of Science ®Google Scholar
• Ruffini C, Locatelli M, Lucca A, et al. Augmentation effect of repetitive transcranial magnetic stimulation over the orbitofrontal cortex in drug-resistant obsessive-compulsive disorder patients: a controlled investigation. Prim Care Companion J Clin Psychiatry 2009;11(5):226-30
   PubMedGoogle Scholar
• Slotema CW, Blom JD, Hoek HW, Sommer IEC. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 2010;71(7):873-84
   PubMed Web of Science ®Google Scholar
• Berlim MT, Neufeld NH, Van den Eynde F. Repetitive transcranial magnetic stimulation (rTMS) for obsessive-compulsive disorder (OCD): an exploratory meta-analysis of randomized and sham-controlled trials. J Psychiatr Res 2013;47(8):999-1006
   PubMedGoogle Scholar
• Mendelsohn D, Lipsman N, Lozano AM, et al. The contemporary practice of psychiatric surgery: results from a Global Survey of Functional Neurosurgeons. Stereotact Funct Neurosurg 2013;91(5):306-13
   PubMed Web of Science ®Google Scholar
• Bear RE, Fitzgerald P, Rosenfeld JV, Bittar RG. Neurosurgery for obsessive-compulsive disorder: contemporary approaches. J Clin Neurosci 2010;17(1):1-5
   PubMedGoogle Scholar
• Leiphart JW, Valone FH 3rd. Stereotactic lesions for the treatment of psychiatric disorders. J Neurosurg 2010;113(6):1204-11
   PubMedGoogle Scholar
• Lopes AC, de Mathis ME, Canteras MM, et al. Update on neurosurgical treatment for obsessive compulsive disorder. Rev Bras Psiquiatr 2004;26(1):62-6
   PubMedGoogle Scholar
• Pan H-C, Sheehan J, Stroila M, et al. Late cyst formation following gamma knife surgery of arteriovenous malformations. J Neurosurg 2005;102(Suppl):124-7
   PubMedGoogle Scholar
• Blomstedt P, Sjöberg RL, Hansson M, et al. Deep brain stimulation in the treatment of obsessive-compulsive disorder. World Neurosurg 2013;80(6):e245-53
   PubMedGoogle Scholar
• Rodriguez-Romaguera J, Do Monte FHM, Quirk GJ. Deep brain stimulation of the ventral striatum enhances extinction of conditioned fear. Proc Natl Acad Sci U S A 2012;109(22):8764-9
   PubMedGoogle Scholar
• US FDA. FDA Approves Humanitarian Device Exemption for Deep Brain Stimulator for Severe Obsessive-Compulsive Disorder. 2009. Available from: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149529.htm
   Google Scholar
• Greenberg BD, Gabriels LA, Malone DA Jr, et al. Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: worldwide experience. Mol Psychiatry 2010;15(1):64-79
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Chakraborty K. Glutamatergic dysfunction--newer targets for anti-obsessional drugs. Recent Patents CNS Drug Discov 2007;2(1):47-55
   PubMedGoogle Scholar
• Goddard AW, Shekhar A, Whiteman AF, McDougle CJ. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discov Today 2008;13(7-8):325-32
   PubMed Web of Science ®Google Scholar
• Fornaro M. Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Ann Gen Psychiatry 2011;10(1):5
   PubMed Web of Science ®Google Scholar
• Matsunaga H, Maebayashi K, Kiriike N. A review of the researches focusing on the heterogeneity of obsessive-compulsive disorder and its potential subtypes. Seishin Shinkeigaku Zasshi 2008;110(3):161-74
   PubMedGoogle Scholar